ClearPoint Neuro, Inc.
CLPT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $31 | $24 | $21 | $16 |
| % Growth | 31% | 16.6% | 26.1% | – |
| Cost of Goods Sold | $12 | $10 | $7 | $5 |
| Gross Profit | $19 | $14 | $14 | $11 |
| % Margin | 60.9% | 56.8% | 65.8% | 68.2% |
| R&D Expenses | $12 | $12 | $11 | $9 |
| G&A Expenses | $12 | $12 | $10 | $8 |
| SG&A Expenses | $26 | $24 | $19 | $15 |
| Sales & Mktg Exp. | $14 | $13 | $9 | $7 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $39 | $36 | $30 | $24 |
| Operating Income | -$20 | -$22 | -$16 | -$13 |
| % Margin | -62.9% | -93.7% | -79.5% | -82.1% |
| Other Income/Exp. Net | $1 | $0 | -$0 | -$1 |
| Pre-Tax Income | -$19 | -$22 | -$16 | -$14 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$19 | -$22 | -$16 | -$14 |
| % Margin | -60.3% | -92.2% | -80% | -88.4% |
| EPS | -0.7 | -0.9 | -0.68 | -0.69 |
| % Growth | 22.2% | -32.4% | 1.4% | – |
| EPS Diluted | -0.7 | -0.9 | -0.68 | -0.69 |
| Weighted Avg Shares Out | 27 | 25 | 24 | 21 |
| Weighted Avg Shares Out Dil | 27 | 25 | 24 | 21 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $2 | $1 | $1 | $1 |
| EBITDA | -$18 | -$21 | -$16 | -$13 |
| % Margin | -56.8% | -87.6% | -75.8% | -78.2% |